Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Change in Cash (2016 - 2025)

Marimed (MRMD) has disclosed Change in Cash for 15 consecutive years, with $458000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Cash rose 213.37% to $458000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$3.2 million, a 8.04% increase, with the full-year FY2024 number at -$7.4 million, down 250.02% from a year prior.
  • Change in Cash was $458000.0 for Q3 2025 at Marimed, up from -$1.1 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $11.9 million in Q1 2023 to a low of -$25.6 million in Q2 2022.
  • A 5-year average of $189315.8 and a median of $458000.0 in 2025 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: skyrocketed 10605.47% in 2021, then crashed 607.26% in 2022.
  • Marimed's Change in Cash stood at $4.1 million in 2021, then plummeted by 133.54% to -$1.4 million in 2022, then skyrocketed by 200.73% to $1.4 million in 2023, then tumbled by 280.81% to -$2.5 million in 2024, then skyrocketed by 118.28% to $458000.0 in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Change in Cash are $458000.0 (Q3 2025), -$1.1 million (Q2 2025), and -$81000.0 (Q1 2025).